Sight Sciences announces results from three manuscripts on treating glaucoma

Sight Sciences (SGHT) announced the results from three key published manuscripts that further demonstrate the value of an interventional mindset in treating glaucoma. The following are notable results from the studies: In a 24-month prospective study of 18 eyes with medication washout at baseline, 12 and 24 months, of standalone OMNI use, mean baseline IOP of 26.1 mmHg was reduced an average of 9.7mmHg at 12 months and 10.6 mmHg at 24 months, while mean medications were reduced from 1.8 to 0.9 and 0.5 at months 12 and 24, respectively; Two-thirds of patients were medication-free at Month 24. In a retrospective, observational study of nearly 13,000 African American eyes, IOP reductions were higher in this study’s MIGS plus cataract surgery cohorts than cataract surgery alone; the proportion of patients with a greater than or equal to 20% reduction in IOP from baseline was greatest for OMNI, followed by Hydrus Microstent and iStent inject. In a subgroup analysis of 220 eyes that had undergone a standalone OMNI procedure in primary open-angle glaucoma, including mild, moderate and severe patients, and both phakic and pseudophakic eyes, IOP was significantly reduced for up to 3 years regardless of lens status or disease severity.